Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.

Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G, Pagano E, Di Marzo V, Izzo AA.

Biochem Pharmacol. 2013 May 1;85(9):1306-16. doi: 10.1016/j.bcp.2013.01.017. Epub 2013 Feb 12.

PMID:
23415610
2.

Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.

Nakase H, Okazaki K, Tabata Y, Chiba T.

J Gastroenterol. 2003 Mar;38 Suppl 15:59-62. Review.

PMID:
12698874
3.

Intestinal drug delivery systems with biodegradable microspheres targeting mucosal immune-regulating cells for chronic inflammatory colitis.

Okazaki K, Nakase H, Watanabe N, Tabata Y, Ikada Y, Chiba T.

J Gastroenterol. 2002 Nov;37 Suppl 14:44-52. Review.

PMID:
12572865
4.

Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.

Greineisen WE, Turner H.

Int Immunopharmacol. 2010 May;10(5):547-55. doi: 10.1016/j.intimp.2010.02.012. Epub 2010 Feb 25. Review.

5.

Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review.

Leinwand KL, Gerich ME, Hoffenberg EJ, Collins CB.

Inflamm Bowel Dis. 2017 Feb;23(2):192-199. doi: 10.1097/MIB.0000000000001004. Review.

PMID:
28079617
6.

Medical cannabis: Another piece in the mosaic of autoimmunity?

Katz D, Katz I, Porat-Katz BS, Shoenfeld Y.

Clin Pharmacol Ther. 2017 Feb;101(2):230-238. doi: 10.1002/cpt.568. Epub 2016 Dec 20. Review.

PMID:
27859024
7.

Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation.

Gyires K, Zádori ZS.

Curr Neuropharmacol. 2016;14(8):935-951. Review.

8.

Berberine and inflammatory bowel disease: A concise review.

Habtemariam S.

Pharmacol Res. 2016 Nov;113(Pt A):592-599. doi: 10.1016/j.phrs.2016.09.041. Epub 2016 Sep 30. Review.

PMID:
27697643
9.

The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease.

Singh UP, Singh NP, Guan H, Busbee B, Price RL, Taub DD, Mishra MK, Fayad R, Nagarkatti M, Nagarkatti PS.

Int Rev Immunol. 2014 Jan;33(1):23-33. doi: 10.3109/08830185.2013.809071. Epub 2013 Jul 10. Review.

10.

Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease.

Naito Y, Takagi T, Yoshikawa T.

J Gastroenterol. 2007 Oct;42(10):787-98. Epub 2007 Oct 15. Review.

PMID:
17940831

Supplemental Content

Support Center